

MVI

overview of progress in clinical development of leading vaccines concept


Christian Loucq, MD

Director, MVI

June 2, 2008




State of Malaria Vaccine Development



**Source: The Malaria Product Pipeline, The George Institute for International Health, September 2007, modified to reflect recent changes in MVI's portfolio*

MVI's Portfolio, *May 2008*



Adjuvanted Recombinant Proteins

Viral Vectored

Live Attenuated



Product Candidates

**Sanaria
PfSPZ**

**ICGEB/BBIL
PvRII**

**GSK
RTS,S
AS01/AS02**

Research Programs

**Monash
MSP4**

**GenVec
Ad5/CSP-
LSA1-Ag2 +
Ad5/MSP1-
AMA1**

**LaTrobe
MSP2
ISA720**

**MVDB
AMA1-C1
ISA720**

**WRAIR/GSK
AMA1
AS01/AS02**

Towards a More Balanced Portfolio

